SAN DIEGO -- aTyr Pharma, Inc. ("aTyr"), today announced the pricing of its initial public offering of 5,360,000 shares of its common stock at an initial public offering price of $14.00 per share. In addition, aTyr has granted the underwriters a 30-day option to purchase up to an additional 804,000 shares of common stock from aTyr at the initial public offering price, less underwriting discounts and commissions. aTyr's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "LIFE" on May 7, 2015. Closing of the offering is expected to occur on or about May 12, 2015, subject to customary closing conditions.
J.P. Morgan Securities LLC and Citigroup Global Markets Inc. are acting as joint book-running managers for the offering. BMO Capital Markets Corp. is acting as lead manager and William Blair & Company, L.L.C. is acting as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on May 6, 2015. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204, or by email at [email protected]; or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email at [email protected] or by telephone at 800-831-9146.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.